Title: Dickkopf-3 is upregulated in osteoarthritis and has a chondroprotective role

Sarah J B Snelling[1] DPhil, Rose K Davidson[2] PhD, Tracey E Swingler[2] PhD, Linh Le[2] PhD, Matthew J Barter[3] PhD, Kirsty L Culley[4] PhD, Andrew Price[1] MA DPhil FRCS (Orth), Andrew J Carr[1] ChM DSc FRCS FMedSci, Ian M Clark[2] PhD

[1]Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
[2]School of Biological Sciences, University of East Anglia, Norwich, UK.
[3]Institute of Cellular Medicine, University of Newcastle, Newcastle, UK
[4]Hospital for Special Surgery and Weill Cornell Medical College, New York,, New York, USA.

Correspondence and reprint requests to: Sarah JB Snelling, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Nuffield Orthopaedic Centre, Windmill Road, Headington, OX3 7LD.
sarah.snelling@ndorms.ox.ac.uk
Tel: 01865 223423

Running title: Dickkopf-3 in osteoarthritis

ABSTRACT

Objective Dickkopf-3 (Dkk3) is a non-canonical member of the Dkk family of Wnt antagonists and its upregulation has been reported in microarray analysis of cartilage from mouse models of osteoarthritis (OA). In this study we assessed Dkk3 expression in human OA cartilage to ascertain its potential role in chondrocyte signaling and cartilage maintenance.

Methods Dkk3 expression was analysed in human adult OA cartilage and synovial tissues and during chondrogenesis of ATDC5 and human mesenchymal stem cells. The role of Dkk3 in cartilage maintenance was analysed by incubation of bovine and human cartilage explants with interleukin-1β (IL1β) and oncostatin-M (OSM). Dkk3 expression was measured in cartilage following murine hip avulsion. Whether Dkk3 influenced Wnt, TGFβ and activin cell signaling was assessed in primary human chondrocytes and SW1353 chondrosarcoma cells using RT-qPCR and luminescence assays.

Results Increased gene and protein levels of Dkk3 were detected in human OA cartilage, synovial tissue and synovial fluid. *DKK3* expression was decreased during chondrogenesis of both ATDC5 cells and humans MSCs. Dkk3 inhibited IL1β and OSM-mediated proteoglycan loss from human and bovine cartilage explants and collagen loss from bovine cartilage explans. Cartilage *DKK3* expression was decreased following hip avulsion injury. TGFβ signaling was enhanced by Dkk3 and Wnt3a and activin signaling were inhibited.

Conclusions We provide evidence that Dkk3 is upregulated in OA and may have a protective effect on cartilage integrity by preventing proteoglycan loss and helping to restore OA-relevant signaling pathway activity. Targeting Dkk3 may be a novel approach in the treatment of OA.

Key words: Cartilage, Wnt, Dickkopf, TGFβ, osteoarthritis

INTRODUCTION

Osteoarthritis (OA) is characterized by loss of articular cartilage, joint pain and instability. The mechanisms regulating disease pathogenesis remain elusive with a combination of genetic, inflammatory, mechanical and metabolic factors implicated.[1-3]

Chondrocytes from OA cartilage exhibit a disrupted phenotype, hallmarks of which include; altered synthesis of extracellular matrix (ECM) and ECM-degrading enzymes, altered cell signaling activity and increased proliferation.[4] Dysregulation of cell signaling pathways likely contributes to OA pathogenesis by reducing the chondrocyte's ability to maintain cartilage integrity, leading to or exacerbating the phenotypic shift associated with OA. The Wnt and TGFβ signaling pathways have been strongly implicated in OA pathogenesis.[5, 6]

Dickkopf-3 (Dkk3) is a structurally and functionally divergent member of the Dkk family of Wnt antagonists. Dkk3 activates or inhibits Wnt signaling in a tissue dependent manner and its impact on cartilage Wnt signaling is unknown.[7-9] Dkk3 is a tumour suppressor that inhibits proliferation of cancer cells and is downregulated in several types of human cancer.[8-10] It can modulate inflammatory cell activity, maintain tissue organisation via TGFβ signaling and can protect against myocardial infarction-induced fibrosis.[11-14]

The function of Dkk3 in other tissues suggests it could be an important mediator of chondrocyte homeostasis and maintenance of cartilage integrity. Several studies using animal models of OA have reported increased Dkk3 in diseased cartilage.[15-17] However Dkk3 expression has not been well characterized in human OA tissue nor has its role in chondrocyte biology been explored. Our aim was to assess whether Dkk3 shows aberrant expression in human OA and to establish whether it can regulate chondrocyte behaviour and OA-associated cartilage degradation *in vitro*.

MATERIALS AND METHODS

Primary tissue

Primary human OA cartilage and synovium were obtained from age-matched individuals undergoing hip replacement for OA and control cartilage and synovium obtained upon hip replacement for neck-of-femur fracture (NOF); cartilage OA n=13, NOF n=12, OA synovium n=8; NOF synovium n=11. Anteromedial OA specimens were obtained from patients undergoing unicompartmental knee replacement for OA. Primary human chondrocytes (HAC) were obtained from macroscopically normal regions of the tibial plateau of OA patients undergoing total knee replacement and collagenase digested following standard protocols. Explants of cartilage were used for proteoglycan and collagen release assays (DMMB and hydroxyproline respectively). Synovial fluid was collected from individuals undergoing total knee replacement (TKR, n=3), unicompartmental knee replacement (UKR, n=3), arthroscopy for cartilage lesions (n=5), matrix-assisted chondrocyte implantation (MACI, n=7) or control patients (n=3) with no cartilage lesion but meniscal tears.

Ethical approval (09/H0606/11 and 2005ORTHO7L) was granted by Oxfordshire Research Ethics Committee and East Norfolk and Waveney Research Governance Committee. Informed consent was obtained from all patients

Cell culture

SW1353 chondrosarcoma cells (ATCC) and primary HAC were cultured in DMEM + 10% (v/v) FCS. ATDC5 cells were cultured in DMEM/F12 (Lonza, UK) containing 5% (v/v) FCS, 2mM glutamine, 10ug/ml apotransferrin (Sigma) and 30nM sodium selenite. Confluent ATDC5 cells were stimulated to undergo chondrogenesis by addition of 10ug/ml insulin (Sigma). Human MSCs (Lonza) were expanded in Mesenchymal Stem Cell Growth Medium (Lonza) supplemented with 5ng/ml fibroblast growth factor-2 (R&D Systems) before high density transwell culture as described.[18, 19] Micromass cultures were established as described [20] before treatment with 100ng/ml Wnt3a for 4 days.

Cartilage explant assays

Bovine nasal septum and human articular cartilage were dissected and 2mm cartilage discs explanted and equilibrated for 24 hours before treatment with IL1β (0.5ng/ml), OSM (5ng/ml) plus Dkk3 (50, 125 and 250ng/ml). Treatments were refreshed every 2-3 days and collected for GAG and collagen release assays. Remaining cartilage was harvested at 14 days for papain digestion and DMMB and hydroxyproline assays.[21] Control and IL1/OSM-treated explants were collected throughout the time course for RNA extraction (Trizol, Invitrogen, UK), subsequent cDNA synthesis (Superscript, Invitrogen UK) according to manufacturer's instructions prior to RT-qPCR. Three intra-experimental replicates were carried out for each treatment condition.

Hip avulsion assay

The hip joint from 5-6 week old C57BL/6J mice was dislocated at the femur and the femoral cap avulsed using forceps as previously described.[22] Hip joint cartilage was cultured for 1-48 hours in serum-free medium before RNA extraction using Trizol (Invitrogen, UK). cDNA synthesis using Superscript (Invitrogen, UK) was performed prior to RT-qPCR.

Immunohistochemistry

Specimens were fixed in 10% (v/v) formalin for 12 hours before decalcification in 5M HNO_3, paraffin embedding and cutting into 5μM sections. Following deparaffinisation and antigen retrieval with 0.2% (v/v) Triton-X 100, sections were blocked and incubated at 4°C overnight in primary antibody (DKK3, R&D Systems, Abingdon, UK) before visualisation using Vectastain ABC (Vector laboratories) with Diaminobenzidine (DAB) and Haematoxylin QS (Vector laboratories).

ELISA

Dkk3 level in synovial fluid was measured using Dkk3 ELISA (R&D Systems, UK) according to manufacturer's instructions.

Cytokine treatments

Cells were serum starved overnight and treated with recombinant IL1β (5ng/ml) and/or OSM(10ng/ml) for 24 hours or pre-treated for 1 hour with recombinant Dkk3 (250ng/ml unless otherwise stated) or carrier alone (R&D Systems) before addition of recombinant Wnt3a (100ng/ml,10 hours), activin (20ng/ml, 6 hours) or TGFβ1 (4ng/ml, 6 hours) (R&D Systems). Three intra-experimental replicates were carried out per cytokine treatment.

Following cytokine treatment cDNA was synthesized using MMLV from DNase-treated cell lysates harvested in Cells-to-cDNA lysis buffer (Ambion) according to manufacturer's instructions.

RT-qPCR

Expression of genes was measured by RT-qPCR on a ViiA7 (Applied Biosystems). Relative quantification is expressed as $2^{-\Delta C_t}$, where ΔC_t is C_t(gene of interest) – C_t(18S rRNA). Samples which gave a Ct reading of 18S +1.5Ct greater or less than the median for 18S were excluded from further analyses.

Luciferase assays

SW1353 chondrosarcoma cells were used for plasmid transfections using Lipofectamine 2000 with the Smad-responsive reporter $(CAGA)_{12}$-luc, Wnt-responsive 8xTCF/LEF binding site (TOPFlash) and mutant TCF/LEF site control FOPFlash and β-galactosidase transfection control plasmid.[23, 24] Cells were treated with Wnt3a (100ng/ml) for 10 hours or TGFβ (4ng/ml) or activin (20ng/ml) for 3 hours with and without 1 hour Dkk3 pre-incubation before measurement of luciferase activity using the Luciferase and Beta-Glo assay systems (Promega).

siRNA

Cells (HAC and SW1353) were transfected with 2.5nM of siRNA against Dkk3 (Qiagen) or Allstars non-targeting negative control (Qiagen) using Dharmafect (Thermoscientific, UK) according to manufacturers instructions. Cells were transfected 48 hours prior to cytokine treatment.

Statistical analysis

Analyses were carried out using Graphpad Prism 6.0. Students t-test was used to test differences between two samples whilst ANOVA with either Dunnett's or Tukey post-test was used for multiple samples. Normality was tested using the Shapiro-Wilk test. $p<0.05$ was considered statistically significant. *≤0.05, **≤0.01, ***≤0.001. Graphs show mean ± 95% confidence intervals of biological (patient or cell) replicates.

RESULTS

Dkk3 expression is upregulated in OA tissue

Expression of *DKK3* mRNA was increased >10-fold ($p<0.0001$) in OA cartilage compared to NOF control (Figure 1A). Analysis of synovium from OA patients

and NOF controls showed a 3.2-fold (p=0.0235) increase in *DKK3* mRNA in diseased tissue. *DKK3* mRNA expression (Figure 1B) was 2.1-fold (p=0.019) higher in damaged cartilage from patients with anteromedial OA (AMG). Our previous work shows reduced *MMP* and *FRZB* mRNA expression in damaged compared to undamaged cartilage.[25] Immunohistochemistry in AMG patients also showed significant Dkk3 staining in the superficial zone of damaged but not undamaged cartilage (Figure 1C). Dkk3 protein (Figure 1D) in synovial fluid was 2.1-fold higher (p=0.0002) in patients undergoing total knee replacement for OA compared to control individuals, those with cartilage lesions (4.33-fold, p<0.0001) or patients undergoing unicompartmental knee replacement (2.83-fold, p=0.0016). Matrix-induced autologous chondrocyte implantation (MACI) is performed 4-6 weeks following initial assessment of cartilage lesions by arthroscopy. Dkk3 levels at the time of MACI were significantly higher than at arthroscopy (i.e. lesion) (2.3-fold, p=0.0029).

DKK3 expression is downregulated following cartilage injury and during chondrogenesis

The OA phenotype includes reinitiation of development [26] ,thus establishing Dkk3 regulation in chondrogenesis is important. ATDC5 differentiation is an established model of chondrogenesis. Following chondrogenic differentiation, microarray analysis showed *Dkk3* expression decreased relative to non-induced control cultures (Figure 2A). Expression of chondrogenic markers *Col2a1* and *Agc1* (data not shown) were increased across these time points.[23] Human MSCs in high density transwell cultures also showed a significant 1.3-21-fold reduction (p<0.01) in *DKK3* expression throughout chondrogenic differentiation into cartilage discs (Figure 2B), with increases in *COL2A1* and *ACAN* across the time course[18].

Joint injury is associated with secondary OA therefore Dkk3 regulation during injury or in response to inflammatory mediators of injury was investigated. *Dkk3* expression in murine cartilage was decreased 1.8-fold (p=0.0005) immediately (1 hour) following hip avulsion injury and remained low (3.54-fold reduction, p<0.0001) 48 hours after injury (Figure 2C). Treatment of HAC for 72 hours with IL1β or the combination IL1β/OSM reduced *DKK3* expression (2.4-fold, p=0.0086 and 5.25-fold. P=0.0009) (Figure 2D), this was partially inhibited by inhibition of p38 MAPK activity (Figure 2E). IL1β/OSM treatment of HAC induced *MMP13* and *MMP1* expression (Figure 2F), this was inhibited by Dkk3 (1.9-fold, p<0.0001 and 3.9-fold, p<0.0001), suggesting Dkk3 inhibits IL1/OSM-induced cartilage degradation via modulation of MMP levels.

Dkk3 prevents cartilage degradation _in vitro_

OA is characterized by loss of proteoglycan and collagen from cartilage ECM. Bovine nasal cartilage (BNC) explants were treated with IL1β/OSM +/- recombinant Dkk3. Cytokine-induced collagen loss (Figure 3A) at day 14 was dose-dependently inhibited by addition of 50, 125 or 250ng/ml Dkk3 (2.0-, 3.6- and 5.6-fold reduction p<0.001) IL1β/OSM-induced proteoglycan loss from BNC

explants was also dose-dependently inhibited by 250ng/ml Dkk3 (1.1-fold, p=0.0049, Figure 3B). Human explants cannot be induced to release collagen however they showed (Figure 3C) significant dose-dependent inhibition of cytokine-induced proteoglycan loss in the presence of 125ng/ml and 250ng/ml Dkk3, (1.6- and 1.5-fold, p=0.003 and p=0.0008, respectively). *DKK3* expression was decreased 1 day after IL1/OSM treatment of BNC explants before increased expression from day 3 onwards (Figure 3D). No toxicity was detected (LDH assay) during 14 days treatment with Dkk3 (data not shown).

Dkk3 inhibits Wnt signaling

Dkk3 is a non-canonical member of the Dkk family of Wnt antagonists with tissue-dependent effects on Wnt signaling activity. To determine whether Dkk3 did regulate Wnt signaling in cartilage we treated HAC with Dkk3 and Wnt3a. The Wnt3a-induced increase of the Wnt target gene *AXIN2* (Figure 4A) was decreased in HAC by co-incubation with Wnt3a and 125, 250 or 500ng/ml Dkk3 (1.6-, 2.2- and 2.5-fold, p=0.0050, <0.0001, <0.0001 respectively) compared to Wnt3a alone. Furthermore the activity of the Wnt-responsive TOPFlash reporter was reduced by the addition of Dkk3 (1.7-fold, p=0.0010) (Figure 4B) compared to Wnt3a alone. Knockdown of Dkk3 in HAC increased Wnt3a-induced *AXIN2* expression compared to a non-targeting siRNA control (Figure 4C). Micromass cultures of HAC show significant reduction in proteoglycan production following Wnt3a treatment for 4 days (Figure 4D). Proteoglycan levels were restored by addition of Dkk3 demonstrating inhibition of Wnt3a-mediated effects on proteoglycan synthesis.

Dkk3 regulates TGFβ signaling

TGFβ signaling responsiveness is reduced in ageing and OA. Expression of the TGFβ-responsive gene, *TIMP3*,[27] was dose-dependently enhanced in HAC treated with TGFβ plus 250 and 500ng/ml Dkk3 compared to TGFβ alone (2.1- and 2.2-fold, p<0.001) (Figure 5A). TGFβ-responsive *PAI1* (Supplementary Figure 2A) and *ADAM12* (data not shown) were also enhanced whilst *MMP13* expression was decreased by TGFβ in combination with 250ng/ml Dkk3 (Figure 5C) compared to TGFβ alone (2.6-fold, p<0.001). 250ng/ml Dkk3 also increased activity of the TGFβ-responsive $(CAGA)_{12}$-luciferase reporter in SW1353 cells relative to TGFβ alone (2.8-fold, p<0.0001) (Figure 5B). No effect of Dkk3 alone was seen on *TIMP3*, *PAI1* or *ADAM12* gene expression or CAGA-luc induction. The extent of TGFβ induction of *TIMP3* (Figure 5D), *PAI1* (Supplementary Figure 1B) and *ADAM12* (data not shown) expression and CAGA-luc (Figure 5E) activity was decreased by Dkk3 knock down. Knockdown of Dkk3 partially repressed the TGFβ-induced decrease of *MMP13* in primary HAC (Figure 5F). p38 MAPK-mediated stabilization of Smad4 has been described in Xenopus laevis ,[28], therefore we inhibited p38 MAPK. The induction of TGFβ-induced *TIMP3* (Figure 5G) and *PAI1* (Supplementary Figure 2B) expression by Dkk3 was abrogated following p38 inhibition in HAC (Figure 5G).

Activin is a member of the TGFβ superfamily that also signals via Smad2/3. To assess whether Dkk3 impacted other Smad2/3-related signaling pathways, HAC and SW1353 were treated with activin +/- Dkk3. Activin induced *TIMP3*

expression and $(CAGA)_{12}$-luc activity whilst co-incubation with Dkk3 caused a dose-dependent reduction in both of these outputs (Figure 6A and 6B). Knockdown of Dkk3 enhanced activin-induced *TIMP3* expression and CAGA-luc activity suggesting endogenous Dkk3 may act to reduce cellular activin-induced responses (Figure 6C and 6D). There was no repression of HAC *TIMP3* expression when p38 MAPK activity was inhibited (Figure 6E).Activin-induced *PAI1* expression followed the same trends as *TIMP3* (Supplementary Figure 3A-C).

DISCUSSION

Altered expression of cytokines and consequent disruption of cell signaling is associated with OA pathogenesis. Dkk3 is a non-canonical member of the Dkk family of Wnt antagonists that has not been explored in cartilage biology despite numerous studies noting its increased expression in models of OA. In this study we demonstrate that Dkk3 is upregulated in adult human OA cartilage and synovial tissue but is decreased during chondrogenesis. Dkk3 protects against *in vitro* cartilage degradation and its expression is regulated by both injury and inflammatory cytokines. Wnt and activin signaling are both inhibited by Dkk3 whilst TGFβ signaling is enhanced. The upregulation of Dkk3 in OA may be a protective mechanism to limit cartilage damage and to regulate aberrant cell signaling associated with disease.

OA is a complex disease affecting multiple joint tissues, with a unique combination of factors likely to regulate pathogenesis within each tissue and across different joint locations. We show that Dkk3 is upregulated in both hip and knee OA and in both synovial tissue and cartilage from diseased joints. Dkk3 upregulation is also reported in OA subchondral bone from patients undergoing TKR.[29] This suggests Dkk3 is relevant to whole joint biology in two common sites of disease. The increased Dkk3 in synovial fluid of patients with tricompartmental OA may implicate Dkk3 as a biomarker distinguishing end-stage disease. Further studies of Dkk3 as a circulating biomarker are warranted.

Dysregulation of Wnt and TGFβ family members has been strongly implicated in experimental and human OA.[5, 6] An imbalance in Wnt signalling leads to OA development in murine models, and Wnt antagonists *DKK1* and *FRZB* have been reported as downregulated in human OA.[30-32] Wnts and activin are also released following cartilage injury.[33, 34] TGFβ signaling and responsiveness decreases with age and OA development whilst increased activin has been detected in OA tissues .[34, 35] Dkk3 has both agonistic and antagonistic effects on the Wnt pathway dependent on tissue of expression and thus investigation of its impact on Wnt signaling in cartilage was investigated in our study.[7-9]. Opposing regulatory roles of Dkk3 on TGFβ signaling in Xenopus and prostate cancer[13, 28] have been reported but its function in musculoskeletal tissue has not been studied

In adult HAC we have shown that Dkk3 antagonized Wnt signaling and protected against Wnt-induced proteoglycan reduction. Dkk3 enhanced TGFβ signaling in chondrocytes and interestingly was necessary for TGFβ-induced reduction of *MMP13* expression. Dkk3 may mediate protective effects on cartilage partially

through upregulation of TGFβ signaling and inhibition of Wnt signaling. Surprisingly, Dkk3 inhibited activin signaling in cartilage despite both activin and TGFβ commonly signaling through Smad2/3. Inhibition of p38 MAPK signaling abrogated the effects of Dkk3 on both TGFβ and activin signaling which shows Dkk3 action here is p38 MAPK dependent. A previous study demonstrated Dkk3-dependent Smad4-stabilization by p38 MAPK and this requires further investigation in chondrocytes.[36] Our data may indicate that Dkk3 effects on TGFβ require p38 MAPK for stabilization of Smad4. The effect of Dkk3 on activin signaling is also p38 MAPK dependent but may operate through a pathway that does not use Smad 4. The mechanism by which differential regulation of activin and TGFβ can occur is currently unknown and beyond the scope of this study.

Injury to the joint commonly leads to OA development. To model cartilage injury *ex vivo* the murine hip was avulsed and Dkk3 levels found to be decreased within 1 hour. Decreased Dkk3 protein was also shown in pilot data from an *ex vivo* porcine explant model [37] following cutting injury (data not shown). Treatment with IL1β/OSM also led to a reduction in Dkk3 expression that was partially p38 MAPK dependent. In contrast, previous reports on murine OA[15-17] and our data in human tissue shows an increase in Dkk3 expression in established disease. Dkk3 may be regulated in a temporal manner during disease pathogenesis. This is supported by our BNC data that shows an initial decrease in *DKK3* expression followed by an increase as cartilage degradation occurs. It is also of note that synovial fluid Dkk3 levels were lower at the time of arthroscopy than 4-6 weeks later when MACI was performed. This may indicate that injury to the joint capsule leads to significant Dkk3 release from other joint tissues that overcomes any decrease due to cartilage injury. The sources of Dkk3 in the joint require further investigation. Any initial injury response leading to decreased Dkk3 may have been completed at MACI and Dkk3 levels are consequently increased in the ensuing repair attempt.

Paralleling the potential roles of the Wnt and TGFβ pathways in OA pathogenesis, chondrogenesis and articular cartilage development require TGFβ signaling as well as regulation of Wnt signaling.[5, 38] Given the reversion of OA chondrocytes to a developmental-like phenotype [39] our data showing decreased Dkk3 during chondrogenesis, shows a potential role for Dkk3 in chondrogenesis, and also suggests that the immediate downregulation of Dkk3 in injury may be an early repair response.

Strikingly, Dkk3 protected against IL1β/OSM-stimulated cartilage degradation. The increase in Dkk3 in OA may be a protective mechanism to minimize cartilage degradation and the OA-associated shift in chondrocyte phenotype. This is supported by the reduction in cartilage-degrading *MMP13* expression by Dkk3 in the presence of IL1β/OSM. Microarray analysis of HAC treated with siRNA against Dkk3 did not reveal pathways of Dkk3 action on unstimulated cells (data not shown), thus future analysis will use cytokine-stimulated. However siRNA treatment did increase *MMP13* expression in TGFβ-treated cells suggesting that Dkk3 may limit cartilage damage partially through reduction of both IL1β/OSM and TGFβ-effects on MMP13.

Overall Dkk3 upregulation in disease may be a defence mechanism to counteract disease-related dysregulation of cell signaling pathways; inhibiting inflammatory cytokine effects on cartilage degradation and enhancing TGFβ signaling whilst maintaining regulation of Wnt signaling in an attempt to counteract disease-associated changes in these pathways. Supplementation with Dkk3 at an early stage of disease or post-injury may therefore be therapeutically beneficial.

Further investigation of Dkk3 in murine models of OA is necessary to ascertain its contribution to cartilage homeostasis and disease pathogenesis. Although the Dkk3 null mouse [40]does not have an overt musculoskeletal phenotype our preliminary analysis suggests increased knee OA in 3- and 6- month old animals, we are currently investigating injury-models of OA. Dkk3 gene therapy is in clinical trial for prostate cancer with promising results,[41] but further preclinical evaluation is necessary alongside more detailed investigation of the role of Dkk3 in other tissues of the healthy and OA joint.

In summary we have demonstrated that Dkk3 is upregulated in human OA and reduces cartilage degradation. These findings may have clinical implications as treatment with Dkk3 may prevent cartilage degeneration in OA and early intervention with Dkk3-based therapy may slow OA progression.

ACKNOWLEDGEMENTS

We thank Chethan Jayadev and Raj Rout for their assistance in cartilage and synovial fluid collection, and Fiona Watt and Anastasios Chanalaris for their assistance with unpublished pilot data on the porcine-injury model.

CONTRIBUTORS

SJBS and IMC designed the study. SJBS, RKD, TES, MJB, KC and LL carried out data acquisition. AJC and AP provided patient samples and assisted with data interpretation. SJBS and IMC carried out data analysis and interpretation. All authors helped prepared the manuscript and approved the manuscript for submission.

FUNDING

Grants: ARUK grants 20087 (SJBS) , 19222 (SJBS), 19424 (MJB) and the NIHR Oxford Musculoskeletal Biomedical Research Unit funded this work

COMPETING INTERESTS

The authors have no competing interests to declare.

REFERENCES

1. Wojdasiewicz P, Poniatowski LA, Szukiewicz D. The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm 2014; 2014: 561459.
2. Andriacchi TP, Favre J. The nature of in vivo mechanical signals that influence cartilage health and progression to knee osteoarthritis. Curr Rheumatol Rep 2014; 16: 463.

3. Loeser RF. Aging processes and the development of osteoarthritis. Curr Opin Rheumatol 2013; 25: 108-113.
4. Goldring MB. The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000; 43: 1916-1926.
5. Staines KA, Macrae VE, Farquharson C. Cartilage development and degeneration: a Wnt Wnt situation. Cell Biochem Funct 2012; 30: 633-642.
6. van der Kraan PM, Goumans MJ, Blaney Davidson E, ten Dijke P. Age-dependent alteration of TGF-beta signalling in osteoarthritis. Cell Tissue Res 2012; 347: 257-265.
7. Nakamura RE, Hunter DD, Yi H, Brunken WJ, Hackam AS. Identification of two novel activities of the Wnt signaling regulator Dickkopf 3 and characterization of its expression in the mouse retina. BMC Cell Biol 2007; 8: 52.
8. Ueno K, Hirata H, Majid S, Chen Y, Zaman MS, Tabatabai ZL, et al. Wnt antagonist DICKKOPF-3 (Dkk-3) induces apoptosis in human renal cell carcinoma. Mol Carcinog 2011; 50: 449-457.
9. Yue W, Sun Q, Dacic S, Landreneau RJ, Siegfried JM, Yu J, et al. Downregulation of Dkk3 activates beta-catenin/TCF-4 signaling in lung cancer. Carcinogenesis 2008; 29: 84-92.
10. Wang Z, Ma LJ, Kang Y, Li X, Zhang XJ. Dickkopf-3 (Dkk3) induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/beta-catenin pathway. Oncol Rep 2015; 33: 1097-1106.
11. Kinoshita R, Watanabe M, Huang P, Li SA, Sakaguchi M, Kumon H, et al. The cysteine-rich core domain of REIC/Dkk-3 is critical for its effect on monocyte differentiation and tumor regression. Oncol Rep 2015; 33: 2908-2914.
12. Meister M, Papatriantafyllou M, Nordstrom V, Kumar V, Ludwig J, Lui KO, et al. Dickkopf-3, a tissue-derived modulator of local T-cell responses. Front Immunol 2015; 6: 78.
13. Romero D, Kawano Y, Bengoa N, Walker MM, Maltry N, Niehrs C, et al. Downregulation of Dickkopf-3 disrupts prostate acinar morphogenesis through TGF-beta/Smad signalling. J Cell Sci 2013; 126: 1858-1867.
14. Zhang Y, Liu Y, Zhu XH, Zhang XD, Jiang DS, Bian ZY, et al. Dickkopf-3 attenuates pressure overload-induced cardiac remodelling. Cardiovasc Res 2014; 102: 35-45.
15. Blom AB, Brockbank SM, van Lent PL, van Beuningen HM, Geurts J, Takahashi N, et al. Involvement of the Wnt signaling pathway in experimental and human osteoarthritis: prominent role of Wnt-induced signaling protein 1. Arthritis Rheum 2009; 60: 501-512.
16. Meng J, Ma X, Ma D, Xu C. Microarray analysis of differential gene expression in temporomandibular joint condylar cartilage after experimentally induced osteoarthritis. Osteoarthritis Cartilage 2005; 13: 1115-1125.
17. Loeser RF, Olex AL, McNulty MA, Carlson CS, Callahan MF, Ferguson CM, et al. Microarray analysis reveals age-related differences in gene expression during the development of osteoarthritis in mice. Arthritis Rheum 2012; 64: 705-717.

18. M J. Barter M, R Gómez, S Woods, W Hui, G R. Smith, D P. Shanley, I M. Clark, D A. Young. Genome-wide microRNA and gene analysis of mesenchymal stem cell chondrogenesis identifies an essential role and multiple targets for miR-140-5p. Stem Cells 2015.
19. Murdoch AD, Grady LM, Ablett MP, Katopodi T, Meadows RS, Hardingham TE. Chondrogenic differentiation of human bone marrow stem cells in transwell cultures: generation of scaffold-free cartilage. Stem Cells 2007; 25: 2786-2796.
20. Greco KV, Iqbal AJ, Rattazzi L, Nalesso G, Moradi-Bidhendi N, Moore AR, et al. High density micromass cultures of a human chondrocyte cell line: a reliable assay system to reveal the modulatory functions of pharmacological agents. Biochem Pharmacol 2011; 82: 1919-1929.
21. Davidson RK, Jupp O, de Ferrars R, Kay CD, Culley KL, Norton R, et al. Sulforaphane represses matrix-degrading proteases and protects cartilage from destruction in vitro and in vivo. Arthritis Rheum 2013; 65: 3130-3140.
22. Chong KW, Chanalaris A, Burleigh A, Jin H, Watt FE, Saklatvala J, et al. Fibroblast growth factor 2 drives changes in gene expression following injury to murine cartilage in vitro and in vivo. Arthritis Rheum 2013; 65: 2346-2355.
23. Swingler TE, Wheeler G, Carmont V, Elliott HR, Barter MJ, Abu-Elmagd M, et al. The expression and function of microRNAs in chondrogenesis and osteoarthritis. Arthritis Rheum 2012; 64: 1909-1919.
24. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 1997; 275: 1784-1787.
25. Snelling S, Rout R, Davidson R, Clark I, Carr A, Hulley PA, et al. A gene expression study of normal and damaged cartilage in anteromedial gonarthrosis, a phenotype of osteoarthritis. Osteoarthritis Cartilage 2014; 22: 334-343.
26. Saito T, Kawaguchi H. HIF-2alpha as a possible therapeutic target of osteoarthritis. Osteoarthritis Cartilage 2010; 18: 1552-1556.
27. Su S, Dehnade F, Zafarullah M. Regulation of tissue inhibitor of metalloproteinases-3 gene expression by transforming growth factor-beta and dexamethasone in bovine and human articular chondrocytes. DNA Cell Biol 1996; 15: 1039-1048.
28. Pinho S, Niehrs C. Dkk3 is required for TGF-beta signaling during Xenopus mesoderm induction. Differentiation 2007; 75: 957-967.
29. Chou CH, Lee CH, Lu LS, Song IW, Chuang HP, Kuo SY, et al. Direct assessment of articular cartilage and underlying subchondral bone reveals a progressive gene expression change in human osteoarthritic knees. Osteoarthritis Cartilage 2013; 21: 450-461.
30. Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, et al. Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice. J Bone Miner Res 2009; 24: 12-21.
31. Zhu M, Chen M, Zuscik M, Wu Q, Wang YJ, Rosier RN, et al. Inhibition of beta-catenin signaling in articular chondrocytes results in articular cartilage destruction. Arthritis Rheum 2008; 58: 2053-2064.

32. Leijten JC, Bos SD, Landman EB, Georgi N, Jahr H, Meulenbelt I, et al. GREM1, FRZB and DKK1 mRNA levels correlate with osteoarthritis and are regulated by osteoarthritis-associated factors. Arthritis Res Ther 2013; 15: R126.
33. Dell'accio F, De Bari C, Eltawil NM, Vanhummelen P, Pitzalis C. Identification of the molecular response of articular cartilage to injury, by microarray screening: Wnt-16 expression and signaling after injury and in osteoarthritis. Arthritis Rheum 2008; 58: 1410-1421.
34. Alexander S, Watt F, Sawaji Y, Hermansson M, Saklatvala J. Activin A is an anticatabolic autocrine cytokine in articular cartilage whose production is controlled by fibroblast growth factor 2 and NF-kappaB. Arthritis Rheum 2007; 56: 3715-3725.
35. van der Kraan PM. Age-related alterations in TGF beta signaling as a causal factor of cartilage degeneration in osteoarthritis. Biomed Mater Eng 2014; 24: 75-80.
36. Hsu RJ, Lin CC, Su YF, Tsai HJ. dickkopf-3-related gene regulates the expression of zebrafish myf5 gene through phosphorylated p38a-dependent Smad4 activity. J Biol Chem 2011; 286: 6855-6864.
37. Gruber J, Vincent TL, Hermansson M, Bolton M, Wait R, Saklatvala J. Induction of interleukin-1 in articular cartilage by explantation and cutting. Arthritis Rheum 2004; 50: 2539-2546.
38. Shen J, Li S, Chen D. TGF-beta signaling and the development of osteoarthritis. Bone Res 2014; 2.
39. van der Kraan PM, van den Berg WB. Chondrocyte hypertrophy and osteoarthritis: role in initiation and progression of cartilage degeneration? Osteoarthritis Cartilage 2012; 20: 223-232.
40. Barrantes Idel B, Montero-Pedrazuela A, Guadano-Ferraz A, Obregon MJ, Martinez de Mena R, Gailus-Durner V, et al. Generation and characterization of dickkopf3 mutant mice. Mol Cell Biol 2006; 26: 2317-2326.
41. Kumon H, Sasaki K, Ariyoshi Y, Sadahira T, Ebara S, Hiraki T, et al. Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC Following Chemotherapy. Clin Med Insights Oncol 2015; 9: 31-38.

FIGURE LEGENDS

Figure 1. Dkk3 levels are altered in OA and during chondrogenesis

(A) *DKK3* expression is elevated in OA cartilage and synovium from patients undergoing total hip arthroplasty. OA cartilage = COA, n=13 NOF control cartilage (CN, n=11) OA synovium (SOA, n=8) and NOF control synovium (SN, n=11). *DKK3* gene (B) and protein (C) levels were elevated in damaged compared to undamaged cartilage from individuals with AMG (n=5), IHC scale bar = 20μM. (D) Dkk3 protein measured by ELISA of synovial fluid was increased in individuals undergoing TKR for OA, n=3. Levels were also measured in individuals with no cartilage lesions (control, n=3), undergoing arthroplasty for cartilage lesions (lesion, n=5), matrix-induced autologous chondrocyte implantation (MACI, n=7) following arthroscopy, or uni- compartmental (UKR, n=3) knee replacement for AMG. (A, B) analysed by t-test, (D) by ANOVA with Tukey post-test, three technical replicates per patient with the mean of these used in statistical analysis and represented as a dot (biological replicate) on each graph..

Figure 2. Dkk3 is regulated by inflammatory cytokines and injury and during chondrogenesis

(A) qRT-PCR of RNA extracted from murine hip cartilage following *ex vivo* avulsion showed a reduction in *DKK3* expression (n=8 mice). (B) 24 hour treatment with IL1β and IL1β/OSM reduced DKK3 expression in primary monolayer HAC (n=4 patients, 4 technical replicates per condition), this was partially inhibited by 10μM of the p38 MAPK inhibitor SB202190 (SB) (n=4 patients, 4 technical replicates per condition) (C). (D) IL1/OSM-induced *MMP13* and *MMP1* expression was inhibited by Dkk3 (n=4 patients, 4 technical replicates per condition). *DKK3* expression was reduced during chondrogenesis of ATDC5 cells (microarray) and human MSCs (RT-qPCR, n=2-3 biological replicates)(E & F). (A-D) and (F) ANOVA with Dunnett's post-test. All statistical analysis carried out on biological replicates.

Figure 3. Dkk3 inhibits *ex vivo* cartilage degradation.

(A)Dkk3 reduced IL1/OSM-induced collagen degradation (hydroxyproline release) from bovine nasal cartilage (BNC) explants (n=4 biological replicates, 3 technical replicates per condition). (B) BNC (n=4) and (C) human knee (n=4) cartilage explants showed a reduction in proteoglycan degradation (GAG release, DMMB assay) in the presence of Dkk3 compared to IL1/OSM treatment alone, 3 technical replicates per condition. *DKK3* expression was significantly reduced in BNC (n=3) at day 1 of IL1/OSM treatment and increased from day 5 onwards. (A), (B) and (C) ANOVA with Dunnett's post-test relative to IL1/OSM alone (D) t-test relative to untreated timepoint control. I/O = IL1/OSM. All statistical analysis carried out on biological replicates (each biological replicate the mean of technical replicates for that sample).

Figure 4. Dkk3 inhibits Wnt signaling in chondrocytes.
(A) HAC (n=4 patients, 3 technical replicates per condition) were treated with Wnt3a with 0-500ng/ml Dkk3 and *AXIN2* expression was reduced in the presence of Dkk3. (B) SW1353 cells were transfected with the TOPFlash reporter plasmid and FOPFlash control. Luminescence was assessed following treatment with Wnt3a, Dkk3 or the combination of Wnt3a and Dkk3. Dkk3 reduced Wnt3a-induced luciferase activity (n=8). (C) Dkk3 inhibited the Wnt3a-induced reduction in proteoglycan production of HAC grown in micromass culture (n=4) as measured by alcian blue staining, mean±SD. (D) Primary HAC (n=4) were treated with siRNA against Dkk3 or negative control siRNA. In the absence of Dkk3 there was a relative increase in Wnt3a-induced *AXIN2* expression. ANOVA with Dunnett's post-test, (A,B, D) significance shown for comparisons of Wnt3a to Wnt3a + Dkk3, (C) significance shown for comparisons of Wnt3a_siRNAcontrol to Wnt3siRNADkk3. n represents biological replicates (the mean of 3 technical replicates per condition for luciferase assays and 4 technical replicates per condition for gene expression assays). All statistical analysis carried out on biological replicates.

Figure 5. Dkk3 enhances TGFβ signaling response.
(A) HAC (n=4) treated with TGFβ showed increased *TIMP3* expression in the presence Dkk3 compared to TGFβ alone. (B) TGFβ-responsive $(CAGA)_{12}$-luciferase activity in SW1353 cells (n=8) was also enhanced by Dkk3 compared to TGFβ alone. TGFβ-induced *TIMP3* expression (C, n=4) and $(CAGA)_{12}$-luciferase activity (D, n=8) was reduced following knockdown of Dkk3. (E) Inhibition of HAC p38 MAPK activity by treatment with 10μM SB202190 (SB) abolished the Dkk3-induced enhancement of *TIMP3* expression following TGFβ treatment (n=3). (F) Dkk3 treatment decreased *MMP13* expression in HAC compared to TGFβ treatment alone (n=4) and siRNA against Dkk3 partially inhibited the TGFβ-induced reduction in *MMP13* expression in HAC (n=4) (G). (A-F)ANOVA with Dunnett's post-test, significance shown for comparison between TGFβ alone and TGFβ + Dkk3 (A-C) and for TGFβ + siControl to TGFβ+ siDkk3 (D-F). (G) ANOVA plus Tukey post-test, significance shown for comparison of TGFβ + Dkk3 to TGFβ alone for with and without SB202190. n represents biological replicates (the mean of 3 technical replicates per condition for luciferase assays and 4 technical replicates per condition for gene expression assays). All statistical analysis carried out on biological replicates.

Figure 6. Dkk3 inhibits activin signaling response
(A) HAC (n=4) treated with activin showed increased *TIMP3* expression in the presence Dkk3 compard to Activin alone. (B) $(CAGA)_{12}$-luciferase activity in SW1353 cells (n=8) was also reduced in the presence of Dkk3 compared to activin alone. Activin-induced *TIMP3* expression (C, n=4) and $(CAGA)_{12}$-luciferase activity (D, n=4) was increased following knockdown of Dkk3. (E) Inhibition of HAC p38 MAPK activity by treatment with 10μM SB202190 (SB) abolished the Dkk3 (250ng/ml)-induced reduction in *TIMP3* expression following Activin treatment (n=4). (A-D) ANOVA with Dunnett's post-test, significance shown for comparison between Activin and Activin + Dkk3 (A, B) and between Activin_siControl and Activin_siDkk3 (C,D). (E) ANOVA with Tukey post-test,

significance shown for comparison between Activin alone and Activin + Dkk3 in the absence and presence of SB202190. n represents biological replicates (the mean of 3 technical replicates per condition for luciferase assays and 4 technical replicates per condition for gene expression assays). All statistical analysis carried out on biological replicates.


A
p<0.001
***
p=0.0235
*
DKK3/18S
0.01
0.001
0.0001
0.00001
CN
COA
SN
SOA
B
p=0.019
*
DKK3/18S
0.1
0.01
U
D
C
Damaged
Undamaged
D
p<0.001
***
p=0.0029
**
p=0.0065
**
p<0.001
***
p=0.016
**
ng/ml Dkk3
300
200
100
0
Control
Lesion
MACI
UKR
TKR


A
Relative Expression
10000
1000
100
Induced
Control
1
5
10
15
21
26
31
26
42
Day
B
p<0.001
***
p=0.0015
**
p=0.0018
**
DKK3/18S
0.0003
0.0002
0.0001
0.0000
-0.0001
0
1
2
3
4
5
6
8
10
12
14
Day
C
p<0.001
***
DKK3/18S
10-4
10-5
10-6
10-7
0 hour
1hour
3 hours
6hours
12 hours
24 hours
48hours
D
DKK3/18S
10
1
0.1
0.01
p=0.0086
*
p<0.001
***
Control
IL1
OSM
IL1/OSM
E
DKK3/18S
10
1
0.1
p<0.001
***
p=0.0146
*
p<0.001
***
Control
IL1/OSM
Control + SB
IL1/OSM + SB
F
Control
IL1/OSM
IL1/OSM + Dkk3
relative gene expression
1000
100
10
1
0.1
0.01
p<0.001
***
p<0.001
***
MMP13
MMP1


A
p<0.001
***
p<0.001
***
%HP release
60
40
20
0
-20
Control
I/O
I/O + 50ng/ml Dkk3
I/O + 125ng/ml Dkk3
I/O + 250ng/ml Dkk3
B
p<0.001
***
p=0.0049
**
% GAG release
100
80
60
40
20
0
Control
I/O
I/O + 50ng/ml Dkk3
I/O + 125ng/ml Dkk3
I/O + 250ng/ml Dkk3
C
p<0.001
***
p<0.001
***
% cumulative GAG release
80
60
40
20
0
Control
I/O
I/O + 125ng/ml Dkk3
I/O + 250ng/ml Dkk3
D
p=0.0163
*
p=0.0003
***
DKK3/18S
100
10
1
0.1
0
5
10
15
Day


A
AXIN2/18S
10
1
0.1
p=0.361
*
p=0.0024
**
p=0.0011
**
Control
Wnt3a
Wnt3a + 125ng/ml Dkk3
Wnt3a + 250ng/ml Dkk3
Wnt3a + 500 ng/ml Dkk3
Dkk3 250ng/ml
B
RLU (TOP/FOP)
10
1
0.1
0.01
p=0.0065
**
Control
Wnt3a
Dkk3
Wnt3a + Dkk3
C
AXIN2/18S
10
1
0.1
p<0.001
***
p<0.001
***
Control_siNegative
Wnt3a_SiNegative
Control_siDkk3_1
Wnt3a_siDkk3_1
Control_siDkk3_2
Wnt3a_siDkk3_2
D
Alcian blue (A595)
150
100
50
0
p<0.001
***
p<0.001
***
Control
Wnt3a
Wnt3a + 125 ng/ml Dkk3
Wnt3a + 250 ng/ml Dkk3


A
B
C
D
E
F
G
TIMP3/18S
RLU
MMP13/18S
p<0.001
***
p=0.0209
*
p=0.0026
**
ns
Control
TGFβ
TGFβ + 125ng/ml Dkk3
TGFβ + 250ng/ml Dkk3
TGFβ + 500ng/ml Dkk3
Dkk3 250ng/ml
TGFβ/Dkk3
Dkk3
TGFβ+Dkk3
Control_siNegative
TGFβ_siNegative
Control_siDkk3_1
TGFβ_siDkk3_1
Control_siDkk3_2
TGFβ_siDkk3_2
TGFβ_siDkk31
TGFβ_siDkk32
Control_siDkk32
TGFβ_sDkk32
Control + SB
TGFβ + SB
TGFβ + Dkk3 + SB


A
TIMP3/18S
10
1
0.1
p<0.001
***
p<0.001
***
p<0.001
***
Control
Activin
Activin + 125ng/ml Dkk3
Activin + 250ng/ml Dkk3
Activin + 500ng/ml Dkk3
Dkk3 250ng/ml
B
RLU
8
6
4
2
0
p=0.0030
**
Control
Activin
Activin + Dkk3
Dkk3
C
TIMP3/18S
1
p=0.0197
*
p=0.0137
*
Control_siNegative
Activin_siNegative
Control_siDkk3_1
Activin_siDkk3_1
Control_siDkk3_2
Activin_siDkk3_2
D
RLU
10
5
0
p<0.001
***
p<0.001
***
Control_siNegative
Activin_SiNegative
Control_siDkk3_1
Activin_siDkk3_1
Control_siDkk3_2
Activin_siDkk3_2
E
TIMP3/18S
1
p=0.0081
**
ns
Control
Activin
Activin +Dkk3
Control + SB
Activin + SB
Activin + Dkk3 + SB


PAI1/18S
100
10
1
0.1
p=0.0241
**
p<0.001
***
p<0.001
***
Control
TGFβ
TGFβ + 125ng/ml Dkk3
TGFβ + 250ng/ml Dkk3
TGFβ + 500ng/ml Dkk3
Dkk3 250ng/ml
p<0.001
***
p=0.0261
*
Control_siNegative
TGFβ_siNegative
Control_siDkk3_1
TGFβ_siDkk31
Control_siDkk32
TGFβ_sDkk32
p=0.0114
*
ns
Control
TGFβ
TGFβ + Dkk3
Control + SB
TGFβ + SB
TGFβ + Dkk3 + SB


A
PAI1/18S
10
1
0.1
p<0.001
p<0.001
p<0.001
***
***
***
Control
Activin
Activin + 125ng/ml Dkk3
Activin + 250ng/ml Dkk3
Activin + 500ng/ml Dkk3
Dkk3 250ng/ml
B
PAI1/18S
10
1
0.1
p=0.0362
p=0.0043
*
**
Control_siNegative
Activin_siNegative
Control_siDkk3_1
Activin_siDkk3_1
Control_siDkk3_2
Activin_siDkk3_2
C
PAI1/18S
10
1
0.1
p=0.0482
ns
*
Control
Activin
Activin +Dkk3
Control + SB
Activin + SB
Activin + Dkk3 + SB